Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Cocrystal Pharma ( (COCP) ) is now available.
Cocrystal Pharma announced on July 10, 2025, that its broad-spectrum protease inhibitor CDI-988 will be featured in an oral presentation at the 9th International Calicivirus Conference in September 2025. The presentation will highlight the Phase 1 study results of CDI-988, a first-in-class oral treatment for noroviruses, showcasing its novel mechanism of action and broad-spectrum antiviral activity. This development positions Cocrystal Pharma as a significant player in the antiviral therapeutics market, particularly for noroviruses, which currently lack approved vaccines or antiviral treatments.
The most recent analyst rating on (COCP) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Cocrystal Pharma stock, see the COCP Stock Forecast page.
Spark’s Take on COCP Stock
According to Spark, TipRanks’ AI Analyst, COCP is a Underperform.
Cocrystal Pharma faces significant financial challenges, with no revenue and ongoing operational losses severely affecting its stock score. The technical analysis indicates potential downward pressure, while the negative valuation metrics are concerning. However, recent corporate events provide some positive aspects, suggesting future growth potential. Overall, the company’s stock score reflects these mixed factors, indicating substantial risk with some long-term opportunities.
To see Spark’s full report on COCP stock, click here.
More about Cocrystal Pharma
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company focused on discovering and developing novel antiviral therapeutics targeting the replication process of influenza viruses, coronaviruses, noroviruses, and hepatitis C viruses. The company employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs.
Average Trading Volume: 18,971
Technical Sentiment Signal: Sell
Current Market Cap: $15.46M
See more data about COCP stock on TipRanks’ Stock Analysis page.